0 citations
The Role of BRAF/MEK Inhibition in Metastatic Malignant Melanoma – a Case Study
Klinicka onkologie2016Vol. 29(2), pp. 133–138
Citations Over Time
Abstract
This case study demonstrates that combination therapy with a BRAF and a MEK inhibitor can be used to successfully treat metastatic malignant melanoma patients and suggests they should be employed in therapeutic algorithms for patients with metastatic malignant melanoma and BRAF gene mutations.
Related Papers
- → Analysis of BRAF Mutation in Primary and Metastatic Melanoma(2005)100 cited
- → The Melanoma Epidemic: More Apparent Than Real?(1997)97 cited
- → Relationship of cell-mediated cytotoxicity against melanoma cells to prognosis in melanoma patients(1978)41 cited
- Epidermotropic metastatic malignant melanoma.(1995)
- → Inhibition of leukocyte migration in agarose by KC1 extracts of a human melanoma cell line grown in serum‐free medium(1975)16 cited